Drugs / Genolair
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06494345 | Jan 2023 → Jun 2024 | allergic asthma | AO GENERIUM | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Genolair | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06494345 ↗ |
| Known as | omalizumab | “Genolair (omalizumab), solution for subcutaneous administration, 150 mg for single subcutaneous administration” NCT06494345 ↗ |
| Action | Inhibit | “it can reduce the amount of free IgE” NCT06494345 ↗ |
| Modality | Monoclonal antibody | “is a humanized recombinant monoclonal antibody” NCT06494345 ↗ |
| Route | Subcutaneous | “solution for subcutaneous administration” NCT06494345 ↗ |